ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy

Journal of the American Society of Nephrology

Volumn 19, Issue 4, 2008, Pages 771-779

  Parving, Hans Henrik ^a   De Zeeuw, Dick ^b   Cooper, Mark E ^c   Remuzzi, Giuseppe ^d   Liu, Nancy ^e   Lunceford, Jared ^e   Shahinfar, Shahnaz ^e   Wong, Peggy H ^e   Lyle, Paulette A ^e   Rossing, Peter ^f   Brenner, Barry M ^g  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d Mario Negri Laboratories and Clinical Research Center   (Italy)

^e MERCK RESEARCH LABORATORIES   (United States)

^f STENO DIABETES CENTER   (Denmark)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATINE; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN; PLACEBO; ACE PROTEIN, HUMAN; ANGIOTENSIN RECEPTOR ANTAGONIST;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; GENETIC POLYMORPHISM; GENETICS; INSULIN DEPENDENT DIABETES MELLITUS; MIDDLE AGED;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; LOSARTAN; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC;

EID: 44349177550     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2007050582     Document Type: Article

References (29)

1. Parving H-H, Mauer M, Ritz E: Diabetic nephropathy. In: Brenner and Rector's The Kidney, 7th ed., edited by Brenner BM, Boston, Saunders, 2004, pp 1777-1818
2. Jacobsen PK: Preventing end stage renal disease in diabetic patients: genetic aspect (part I). J Renin Angiotensin Aldosterone Syst 6: 1-14, 2005
3. Rigat B, Hubert C, henc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346, 1990
4. van der Kleij FG, de Jong PE, Henning RH, de Zeeuw D, Navis G: Enhanced responses of blood pressure, renal function, and aldosterone to angiotensin I in the DD genotype are blunted by low sodium intake. J Am Soc Nephrol 13: 1025-1033, 2002
5. Luik PT, Hoogenberg K, Kerstens MN, Beusekamp BJ, de Jong PE, Dullaart RP, Navis GJ: The influence of the ACE (I/D) polymorphism on systemic and renal vascular responses to angiotensins in normotensive, normoalbuminuric Type 1 diabetes mellitus. Diabetologia 46: 1131-1139, 2003
6. Ng DP, Tai BC, Koh D, Tan KW, Chia KS: Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia 48: 1008-1016, 2005
7. Parving H-H, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, Cambien F: Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ 313: 591-594, 1996
8. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving H-H: Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol 14: 2843-2850, 2003
9. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, Parving H-H: Long-Term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype? Diabetes Care 26: 1501-1506, 2003
10. Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving H-H: The losartan renal protection study: rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone System 1: 328-335, 2000
11. de Zeeuw D, Ramjit D, Zhang Z, Ribeiro AB, Kurokawa K, Lash JP, Chan J, Remuzzi G, Brenner BM, Shahinfar S: Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL Kidney Int 69: 1675-1682, 2006
12. GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863, 1997
13. Perna A, Ruggenenti P, Testa A, Spoto B, Benini R, Misefari V, Remuzzi G, Zoccali C: ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies. Kidney Int 57: 274-281, 2000
14. Ruggenenti P, Perna A, Zoccali C, Gherardi G, Benini R, Testa A, Remuzzi G: Chronic proteinuric nephropathies: II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol 11: 88-96, 2000
15. Scharplatz M, Puhan MA, Steurer J, Perna A, Bachmann LM: Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review. Curr Control Trials Cardiovasc Med 6: 16, 2005
16. Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G: Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis 35: 1155-1165, 2000
17. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH: Progression of nephropathy in type 2 diabetic patients. Kidney Int 66: 1596-1605, 2004
18. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R: The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63: 1499-1507, 2003
19. Jacobsen PK, Tarnow L, Parving HH: Time to consider ACE insertion/ deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int 69: 1293-1295, 2006
20. Yoshida H, Kuriyama S, Atsumi Y, Tomonari H, Mitarai T, Hamaguchi A, Kubo H, Kawaguchi Y, Kon V, Matsuoka K, Ichikawa I, Sakai O: Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50: 657-664, 1996
21. Wang Y, Ng MC, So WY, Tong PC, Ma RC, Chow CC, Cockram CS, Chan JC: Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care 28: 348-354, 2005
22. Solini A, Dalla VM, Saller A, Nosadini R, Crepaldi G, Fioretto P: The angiotensin-converting enzyme DD genotype is associated with glomerulopathy lesions in type 2 diabetes. Diabetes 51: 251-255, 2002
23. Weinshilboum R: Inheritance and drug response. N Engl J Med 348: 529-537, 2003
24. Evans WE, McLeod HL: Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 348: 538-549, 2003
25. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong LA, Fuller JH: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 47: 1507-1511, 1998
26. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, Lam CW, Chow CC, Chan WB, Kong AP, Chan JC: Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients: interaction with ACE insertion/ deletion polymorphism. Kidney Int 69: 1438-1443, 2006
27. Lajer M, Tarnow L, Andersen S, Parving H-H: Polymorphism predicts blood pressure lowering response to losartan treatment in Caucasian type 1 diabetic patients with diabetic nephropathy [Abstract]. J Am Soc Nephrol 16: 590A, 2005
28. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H-H: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
29. Soubrier F, Martin S, Alonso A, Visvikis S, Tiret L, Matsuda F, Lathrop GM, Farrall M: High-resolution genetic mapping of the ACE-linked QTL influencing circulating ACE activity. Eur J Hum Genet 10: 553-561, 2002